Quantile regression to characterize solanezumab effects in Alzheimer's disease trials

INTRODUCTION: In two solanezumab trials for mild-to-moderate Alzheimer's disease (AD) dementia, 27% of patients had biomarker confirmation of amyloid status. Of these, approximately 25% of mild patients and approximately 10% of moderate patients were amyloid negative and, as a group, did not ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yun-Fei, Ma, Xiwen, Sundell, Karen, Alaka, Karla, Schuh, Kory, Raskin, Joel, Dean, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651345/
https://www.ncbi.nlm.nih.gov/pubmed/29067306
http://dx.doi.org/10.1016/j.trci.2016.07.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651345/
https://www.ncbi.nlm.nih.gov/pubmed/29067306
http://dx.doi.org/10.1016/j.trci.2016.07.005

Ejemplares similares